<DOC>
	<DOCNO>NCT01063621</DOCNO>
	<brief_summary>This extend long-term safety study Parkinson 's disease patient motor response complication levodopa therapy complete 12 week administration KW-6500 6500-004 study . The safety efficacy long-term subcutaneous self-injections KW-6500 evaluate .</brief_summary>
	<brief_title>Extended Long-Term Safety Study KW-6500</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients give write informed consent Patients complete 6500004 study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>